Investigation of the humoral and cellular immunity against SARS-CoV2 in patients after kidney transplantation in pandemic times
- Conditions
- U07.1COVID-19, virus identified
- Registration Number
- DRKS00024171
- Lead Sponsor
- niversitätsklinikum Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 46
Patients after kidney transplantation:
- All patients over the age of 16 who are regularly treated in our outpatient clinics
- Present written declaration of consent.
Patients end stage kidney disease:
- All patients who are preparing for a kidney transplant at our center. The minimum age is set at 16 years.
- Present written declaration of consent.
- Controll group:
Present written declaration of consent.
- Persons who are in a dependent / working relationship with the examiners, in particular employees of the clinics and institutes involved
- Current infection with SARS-CoV2 (positive PCR result)
- Inability to consent, e.g. due to language barriers or mental illness
- Placement in an institution based on a judicial or administrative order
- Controll group: people who suffer from chronic kidney disease chronic immunosuppression
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method · Differences of the cellular and humoral immunity against SARS-CoV2 in the KTx group compared to the two control groups<br>· Does the cellular and humoral immunity correlate with the frequency of SARS-CoV2 infections?
- Secondary Outcome Measures
Name Time Method · Differences between living donation and post mortem donation?<br>· Group differences between patients before and after kidney transplantation<br>· Influence of immunosuppressants on the cellular and humoral immune response<br>· Influence of relevant events during the follow-up (e.g. vaccination, changes in immunosuppression) on cellular and humoral immunity